ENDRA Life Sciences Inc
Company Profile
Business description
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Contact
3600 Green Court
Suite 350
Ann ArborMI48105-1570
USAT: +1 734 335-0468
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,399.80 | 30.50 | 0.36% |
| CAC 40 | 7,626.84 | 70.08 | -0.91% |
| DAX 40 | 23,115.96 | 133.69 | -0.58% |
| Dow JONES (US) | 41,212.14 | 383.14 | 0.94% |
| FTSE 100 | 8,559.33 | 38.09 | -0.44% |
| HKSE | 22,691.88 | 29.17 | 0.13% |
| NASDAQ | 17,689.32 | 0.34 | -0.00% |
| Nikkei 225 | 36,779.66 | 51.03 | -0.14% |
| NZX 50 Index | 12,496.89 | 75.80 | 0.61% |
| S&P 500 | 5,631.31 | 24.40 | 0.44% |
| S&P/ASX 200 | 8,178.30 | 26.90 | 0.33% |
| SSE Composite Index | 3,342.67 | 26.55 | 0.80% |